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An audit to determine the clinical 
efectiveness of a pathway for managing 
wound infection.
W
ound management accounts for 
a large proportion of community 
nurses’ clinical workload (Dowsett, 
2009); community nurses are therefore well placed 
to identify patients at increased risk of wound 
infection, make a clinical diagnosis and initiate 
treatment. Community nurses require access to clear 
and concise wound management guidance that has 
been developed using the best available evidence 
(Gottrup et al, 2013), to maintain patient safety, 
and to support accurate and consistent assessment, 
care and ongoing evaluation  (Grothier and Ousey, 
2014). To meet this requirement, one community 
services provider introduced a colour-coded clinical 
pathway for managing wound infection (Figure 1), 
with the aims of increasing clinicians’ confidence in 
decision-making and ensuring patients were treated 
safely and consistently (Grothier and Ousey, 2014). 
The pathway aimed to identify patients at high risk of 
wound infection, including those with (World Union 
of Wound Healing Societies [WUWHS], 2008):
 Impaired immune response
 Comorbidities affecting tissue perfusion
 Obesity
 Poor nutrition 
 Psychological factors 
 Localised wound factors. 
The tool aimed to prevent these high-risk patients 
from developing an infection. A previous pilot 
audit had indicated some positive results with 
regard to infection prevention in high-risk 
patients and a reduction in symptoms (Grothier 
and Shields, 2012). Therefore, it was felt that a 
further larger audit study was required to establish 
clinical effectiveness and risk reduction. The study 
was carried out within the tissue viability centre 
to allow for consistency in care provision and 
data collection. The tissue viability service is a 
community referral service for patients considered 
to be complex or non-healing within the individual 
expected time frame. Referrals can be made by any 
health professional for patients registered with a 
GP within the geographical area, including adults 
and children.
THE TOOL
To support the identification and timely 
intervention of patients at high risk of infection 
or with critically colonised wounds, the pathway 
encourages clinicians to use specific products 
prophylactically as a prevention strategy (green and 
amber pathways). 
METHODS
Data were collected on patients presenting with 
a wound at the tissue viability centre between 
January 2013 and March 2014. Patients were 
classified for wound management purposes as 
being on one of the following pathways:
 Red: presenting with an established infection
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Prevention of wound infection is a key objective in the planning of care for patients 
with wounds. The potential for wound infection, particularly in chronic wounds 
that are heavily contaminated with bacteria, can be high (Bowler et al, 2001). Wound 
infection can negatively affect the patient experience, causing pain, delayed healing 
and poor clinical outcomes (Butcher, 2011). This article outlines the introduction of 
a clinical pathway for identifying and managing wound infection in a community 
nursing service. The article sets out the results of an audit to investigate the efficacy 
of the pathway, and discusses the importance of identifying and managing wound 
infection risk in patient care.
KEY WORDS
 Wound management
 Infection risk
 Clinical pathway 
 Audit
Wounds UK | Vol 11 | No 2 | 2015 31
RESEARCH AND AUDIT
Infected RED Pathway Critically colonised AMBER Pathway High risk of recurrence GREEN Pathway
Do you consider the wound to be  
critically colonised?
• Malodour
• Abnormal / absence of viable tissue
• Excessive or increased serous exudate
• Possible extension of wound dimensions
• Static wound
• No fever
Is the patient at high risk of developing an 
infection or has there been two or more 
episodes of recurrence within the wound  
that is being treated?
• Follow protocol for wound swabbing
• Ensure antibiotic therapy is compliant  
 with local formulary or advice has been  
 sought from a Medical Microbiologist  
 if there is a variance.
Commence an
antimicrobial 
dressing
Please refer to the local  
formulary
• Use Prontosan to cleanse the  
 wound and to help minimise the  
 risk of further complications.
Step 1:  
Prontosan
• Commence use of Cutimed 
 Sorbact to prevent infection  
 or recurrence.
Step 2:  
Cutimed Sorbact 
Review Period
Review the wound after two weeks. 
Is the wound showing two or more signs of infection? 
If yes, have you assessed the following?
•  TIME framework?
•  Appropriate level of compression?
•  Appropriate wound management?
•   Is the patient following the correct colour pathway?
If yes, document full rationale in the nursing notes and continue 
for a futher two weeks. 
If, after four weeks of treatment there is no improvement,  
re-swab the  wound and refer to the Tissue Viability / Infection 
Control teams.
Review  
Process
• Review the formulary and product  
 selection every two weeks including a full  
 rationale in the nursing notes as to why you  
 have continued /discontinued treatment.
•  If the wound fails to progress or deteriorates  
 please refer to the Tissue Viability team and  
 consider the red pathway.
Discontinue treatment
Have any of the following occured?
•  Reduction in wound dimensions
•  Reduction in exudate levels
•  Reduction in pain
Once bioburden is under control and the wound is improving, 
a non-antimicrobial dressing should be considered. 
Document full rationale in the nursing notes.
Continue treatment
Have you assessed the following?
•  TIME Framework
•  Appropriate level of compression?
•  Appropriate wound management?
•   Have you identiied the cause of the wound?
Document full rationale in the nursing notes. 
If, after four weeks of treatment there is no improvement,  
reassess the wound for the red and amber pathway, swab  
the wound and refer to Tissue Viability/ Infection Control.
Developed by: Lorraine Grothier, Consultant Nurse Tissue Viability/Service Manager. 
Acknowledgments:  Andrew Kingsley - Clinical Manager Infection Control and 
Tissue Viability, Northern Devon Healthcare Trust. Julia Shields - Infection 
Prevention Lead Nurse, Provide.
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References: Best Practice Statement: Second Edition, May 2011. The use of 
topical antiseptic antimicrobial agents in wound management. International 
Consensus: Appropriate use of silver dressings in wounds. An expert working 
group consensus. Wounds International 2012.
• For acute cellulitis, please refer to the  
 cellulitis pathway
• For diabetic foot ulcers, refer to the  
 diabetic foot ulcer pathway
Do you consider the wound to be infected?
• Erythema, odema
• Swelling, localised heat
•  Severe or increased pain at the wound site and  
 surrounding tissues
• Excessive, purulent exudate
•  Increase in wound dimensions, tunnelling, or pocketing  
 at the base of the wound
•  Discolouration of the wound bed, visible devitialised tissue
• Malodour
• Fever, systemic symptoms
Tissue Viability Service
Pathway for Managing Wound Infection
• Use Prontosan to cleanse the  
 wound and to help minimise the  
 risk of further complications.
Step 1:  
Prontosan
• Commence use of Cutimed 
 Sorbact to prevent infection  
 or recurrence.
Step 2:  
Cutimed Sorbact 
Figure 1: Pathway for managing wound infection (with kind permission from Provide CIC)
 Amber: presenting with wounds that were 
critically colonised
 Green: deemed to be at high risk of wound 
infection recurrence, defined as two or more 
infections in the same wound, but who did 
not have an infection.
Several characteristics relating to the wound 
and its treatment were recorded for each patient 
including wound type, location and duration, the 
location of treatment and the personnel involved 
in the treatment. 
An audit review was undertaken on each patient, 
after 4 weeks, at which point each wound was re-
classified if necessary onto either the red, amber or 
green pathways.
The sample at baseline was summarised 
descriptively. Substantive differences in the 
characteristics of wounds on different pathways 
at baseline were assessed. Changes in a number 
of wound parameters between baseline and the Figure 2: Number of wounds assigned to each pathway at baseline
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Table 1. Baseline sample characteristics
Variable Frequency (%)*
Treatment location
• Community hospital
• GP practice
• Patient’s home/residential home
• Tissue viability clinic
• 4 (2.7%)
• 2 (1.4%)
• 13 (8.8%)
• 128 (87.1%)
Treatment personnel
• Health care assistant
• Registered nurse
• Tissue viability nurse
• 18 (12.2%)
• 8 (5.4%)
• 121 (82.3%)
Personnel deciding treatment plan
• Community nurse/RGN   
• Tissue viability nurse
• 8 (5.4%)
• 139 (94.6%)
Wound type
• Leg ulcer
• Pressure ulcer
• Surgical wound
• Wet leaking leg
• Others 
• 120 (81.6%)
• 7 (4.8%)
• 6 (4.1%)
• 9 (6.1%)
• 5 (3.4%)
Wound duration
• Less than 3 months
• 3–6 months
• 6 months–1 year
• 1–2 years
• 2–3 years
• 3+ years
• 34 (23.1%)
• 18 (12.2%)
• 29 (19.7%)
• 26 (17.7%)
• 20 (13.6%)
• 20 (13.6%)
Recurrence of previous wound 
• Yes
•  No
• 59 (48.0%)
• 64 (52.0%)
Wound pathway at baseline
• Red
• Amber
• Green
• 28 (19.0%)
• 27 (18.4%)
• 92 (62.6%)
Patient currently on antibiotics 
• Yes
• No
• 17 (11.6%)
• 129 (88.4%)
Patient had antibiotics in previous 12 weeks 
• Yes
•  No
• 67 (45.9%)
• 79 (54.1%)
Patient had a swab taken 
• Yes
• No
• 61 (41.8%)
• 85 (58.2%)
Exudate level 
• None
• Low
• Moderate
• High
• 1 (0.7%)
• 29 (19.9%)
• 92 (63.0%)
• 24 (16.4%)
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4-week audit were recorded, where applicable. 
The primary analysis was undertaken on wounds 
assigned to the green pathway at baseline, to assess 
the significance of any differences in characteristics 
of wounds remaining on the green pathway at the 
4-week audit, and those re-classified from the 
green pathway to be on the amber or red pathways 
at the 4-week audit, using binary logistic regression 
analysis.  The research hypothesis was that wound 
progression would be significantly associated with 
wound characteristics, with the expected direction 
of the association being that those wounds showing 
more diversity of improvement would be more 
likely to retain the green pathway classification.
RESULTS 
Data were collected on 151 wounds. Four wounds 
were not assigned to a pathway at baseline and 
were deleted from further analysis, leaving 147 
usable records. Over half of all wounds (92; 
62.6%) were assigned to the green pathway; of the 
remainder, approximately equal numbers were 
assigned to the red (28; 19.0%) and amber (27; 
18.3%) pathways (Figure 2).
Summary of sample at baseline
The majority of patients received treatment in 
a tissue viability clinic, with a nurse specialist 
providing treatment and making decisions about 
the treatment plan. Most treated wounds were leg 
ulcers, with an approximately even distribution of 
wound duration times from less than 3 months to 
over 3 years. Just over one third of all wounds were 
less than 6 months old; just over one third were 6 
months to 2 years old; and the remaining wounds 
were 2 years or over. 
Approximately half of all recorded wounds were 
recurrences of previous wounds. A significant 
minority of patients had either taken antibiotics 
within the previous 12 weeks and/or had had a 
swab taken.
The sample characteristics as recorded at baseline 
are summarised descriptively in Table 1. There 
were gaps in variable data for a small number of 
patients due to incomplete data forms, and therefore 
percentages are calculated using the number of 
patients who had a recorded variable. Where data 
was not collected for all 147 patients, the number of 
patients with recorded variables is documented.
Some substantive differences in the 
characteristics of wounds were observed between 
those designated to the green, amber and red 
pathways at baseline. Wounds allocated to the red 
pathway were more likely to be associated with a 
current systemic antibiotic therapy than those on 
other pathways: 11 out of 28 red pathway wounds 
(39.3%) were associated with current systemic 
antibiotic therapy, compared with 3 out of 27 
(11.1%) of amber pathway wounds and  3 out of 28 
(10.7%) green pathway wounds (Figure 3).
More than half (15 out of 28; 53.6%) of all red 
pathway wounds were recurrences, compared to 
Table 1 (cont). Baseline sample characteristics
Variable Frequency (%)*
Odour level 
• None
• Low
• Moderate
• High
• 94 (64.4%)
• 35 (24.0%)
• 16 (11.0%)
• 1 (0.7%)
Frequency of dressing change (times per week)
• 1
• 2
• 3–6
• 7+
• 6 (10.9%)
• 86 (58.5%)
• 29 (19.7%)
• 16 (10.9%)
Number of hospital admissions within last 6 months    
• 0
• 1
• 2+
• 120 (82.8%)
• 19 (13.1%)
• 6 (4.1%)
*Percentages calculated using the number of patients who had a recorded variable
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7 out of 27 (25.9%) of amber pathway wounds, and 37 
out of 92 (40.2%) green pathway wounds (Figure 4).
There were no substantive differences in the 
locations of wounds on different pathways, with 
77–85% of wounds on each pathway being leg ulcers.
CHANGES TO DESIGNATED WOUND 
PATHWAYS BETWEEN BASELINE 
ASSESSMENT AND 4-WEEK AUDIT.
The following analysis was undertaken on the 
128 patients who remained on the pathway at the 
4-week audit; patients no longer on the pathway 
were not included as it would be expected that 
removal of a patient from the pathway would be for 
a positive wound outcome. 
Of the 92 wounds assigned to the green pathway 
at baseline, 79 (85.6%) were still on a pathway at 
the 4-week audit. Of these 79 wounds, 70 (88.6%) 
remained on the green pathway, 5 (6.4%) had been 
transferred to the amber pathway and 4 (5.1%) had 
been transferred to the red pathway. 
Of the 27 wounds assigned to the amber 
pathway at baseline, 20 (69.0%) were still on 
a pathway at the 4-week audit. The majority 
(15; 75.0%) of these wounds had transferred to 
the green pathway at this point, indicating an 
improvement in status, with only four (20.0%) 
remaining on the amber pathway and one wound 
(5.0%) being transferred to the red pathway.
Of the 28 wounds assigned to the red pathway 
at baseline, 24 (85.7%) were still on a designated 
pathway at the 4-week audit. The majority (15; 
62.5%) of these wounds had transferred to the 
green pathway at this point, indicating a strong 
improvement in status. A further three wounds 
(12.5%) had been transferred to the amber pathway, 
also indicating status improvement. Six wounds 
(25.0%) remained on the red pathway.
The progress of all wounds between baseline 
and 4 weeks, for those wounds remaining on the 
pathway after 4 weeks, is summarised in Table 2.
The status of 80 out of 128 (62.5%) wounds 
were unchanged, the status of 38 wounds 
improved (29.7%), and the status of 10 wounds 
(7.8%) worsened. 118 out of 128 wounds (92.2%) 
did not experience deterioration in status over the 
4-week period.
Progress in wound parameters from baseline 
to 4-week audit
The majority of wounds as assessed by the tissue 
viability staff showed improved healing progression 
over the 4-week period, with only 7% of all wounds 
reported to be indicating decreased wound healing. 
An improvement was represented by a decrease in 
symptoms. Symptoms included pain, malodour and 
exudate; a reduction was observed in more than half 
of all wounds. The parameter in which the greatest 
proportions of wounds were seen to improve was 
exudate level (Gottrup et al, 2013): decreased levels 
Figure 3: Percentage of wounds on each pathway associated with systemic antibiotic 
therapy at baseline
Figure 4: Percentage of recurrent wounds on each pathway
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Figure 5: Percentage of wounds in excess of 1 year duration on each pathway
Table 2. Summary of pathway changes in 4 weeks from baseline assessment for all wounds
Wound pathway at baseline  
(frequency)
Wound pathway after 4 weeks frequency
Red Amber Green
Red 8 3* 15*
Amber 1** 4 20*
Green 4** 5** 70
*Represents an improvement in status 
**Represents a deterioration in status
were reported in about two thirds of all wounds, 
with a further quarter showing no change.
Changes in wound characteristics from baseline 
(where applicable) are summarised in Table 3.
Analysis of wounds assigned to green 
pathway at baseline
Of the 79 wounds that were assigned to green 
pathway at baseline, the characteristics of 
those which remained classified as being on 
the green pathway at 4 weeks ('static' wounds) 
were compared with the characteristics of those 
which were transferred to either the amber or red 
pathways ('deteriorating' wounds). 
No significant associations were found between 
wound status (i.e. static or deteriorating) and any 
of the following characteristics: wound location 
(classified as leg ulcer or other); wound duration 
(less than 1 year, or 1 year or more); whether or not 
the wound was a recurrence of a previous wound; 
or whether or not the patient had taken antibiotics 
at any time in the previous 12 weeks. However, 
while none of the 14 non-leg ulcer wounds 
changed status, 9 out of 64 (14.1%) leg ulcers did so.
An uncontrolled logistic regression analysis 
identified a significant association between 
improvement in specific wound parameters 
(considered to be represented by the number 
of parameters for which an improvement was 
recorded) and wound status (P=0.003; odds ratio 
= 0.11; 95% confidence for odds ratio: [0.03, 0.49]. 
Hence the wound pathway classification, which 
is a summary measure of wound characteristics, 
appears to be consistent with expectations from 
the analysis of individual characteristics, in that the 
fewer improving parameters are recorded, the less 
likely it is that the wound pathway is downgraded 
from the 'static' (i.e. green) state. A logistic 
regression analysis to investigate the significance of 
any relationship between wound status and wound 
progression could not be conducted, as all wounds 
whose pathway status was reduced from green to 
either amber or red were recorded as not having 
wound healing progression.
Costs
The annual spend for this local organisation in 
2011/12 for products associated with treating 
wound infection before the introduction of the 
Table 3. Changes in wound parameters over 4-week period
Wound parameter Frequency (%)*
Increase Decrease Stayed the 
same
Exudate Level 10 (7.8%) 85 (66.4%) 33 (25.8%)
Erythema, oedema 6 (17.6%) 18 (52.9%) 10 (29.4%)
Malodour 8 (19.5%) 22 (53.7%) 11 (26.8%)
Pain 12 (16.9%) 45 (63.4%) 14 (19.7%)
Swelling, localised heat 5 (22.7%) 14 (63.6%) 3 (13.6%)
Wound size 12 (10.9%) 66 (60.0%) 32 (29.1%)
% of slough / necrosis 17 (25.0%) 40 (58.8%) 11 (16.2)
Fever, systemic symptoms 0 (0.0%) 3 (42.9%) 4 (57.1%)
Wound healing progression 75 (58.6%) 9 (7.0%) 44 (34.4%)
*Percentages calculated using the number of patients who had a recorded variable
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colour-coded pathway was reported in excess 
of £130,000 inclusive of silver, iodine and honey 
dressings. Following introduction of the pathway, 
this figure reduced to £68,447 during 2013/14 for 
products used to treat active wound infection (red 
pathway), suggestive that practice has improved for 
appropriate treatment of infected wounds. 
Within the amber and green elements of the 
pathway, an additional spend of £88,517 was noted 
on products that could be safely used for prolonged 
periods of time (Haycocks et al, 2011). However, 
for 2013/14, the total cost of dressings remained at 
£38,657 under the allocated budget of £1.2 million, 
despite activity increasing by 42% within all services 
accessing dressing products paid for within this 
budget (Provide Knowledge Management, 2015).
DISCUSSION
The audit findings suggest that the pathway is 
effective in preventing patients with wounds 
considered to be at high risk of infection—on the 
green pathway—from entering the red pathway. 
It is apparent that the majority of wounds either 
move towards green pathways or stay the same, 
particularly those already on green at initial 
assessment. The audit findings suggest that infection 
or critical colonisation was prevented over a 
4-week period in nearly 90% of high-risk patients 
initially assigned to the green pathway. Using a 
polyhexamethylene biguanide (PHMB) cleanser 
and a dialkylcarbamoylchloride (DACC) dressing 
product prophylactically, even for longer periods, has 
had no detrimental effect on the patients treated in 
this audit and is suitable for patients of all age groups. 
Using this pathway approach, more interactive 
antimicrobial dressing products are reserved for 
active treatment for established wound infection. 
Therefore, the potential for resistance or any other 
potential negative effects are reduced. 
The financial costs associated with wound 
management are also an important consideration 
and need to be viewed within the context of 
appropriate practice and patient outcomes 
(National Prescribing Centre [NPC], 2012). 
The audit data suggest that managing patients 
appropriately and preventing infection reduces 
the use of expensive antimicrobials and other 
dressings used for symptom management such 
as super absorbents to manage increased levels 
of exudate. Investing in patient safety potentially 
reduces the costs associated with unplanned 
admission to secondary care, or the need for 
increased clinical intervention in the community.
CONCLUSION 
The National Institute for Health and Care 
Excellence (NICE, 2015) is developing guidelines 
on antimicrobial stewardship and antimicrobial 
resistance, which will recommend prudent 
prescribing. This is necessary as few new antibiotics 
are being developed and there is a need to ensure 
that resistance to current treatment is minimised 
(NICE, 2015). Identifying patients who are at 
increased risk of wound infection and developing 
and implementing safe effective prophylactic 
treatment at the earliest possible stage of care can 
help to reduce the need for systemic antibiotics. 
The impact of implementing the pathway has 
demonstrated an increase in staff awareness within 
the tissue viability team of the risks associated 
with wound infection and their responsibilities 
with regard to developing the most appropriate 
care plan. Early detection and intervention ensures 
patient safety remains a high priority. A further 
study is planned to review the use of the pathway in 
clinical practice by generalist nurses and to establish 
if knowledge and confidence in decision-making 
has been maintained since its implementation.
CASE STUDY 
The patient is a 66-year-old, immunosuppressed 
male who initially presented to the Tissue Viability 
team in February 2007 with non-progressing 
lesions to his left leg. Past medical history 
comprised lymphoma, a course of radiotherapy 
in 2010, multiple allergies and psoriasis, which is 
being treated by the Dermatology team. There had 
been recurrent episodes of wound infection, which 
Figure 6: Case study wound incidence of infection Jan–Aug 2012  
and Jan–Aug 2013
Jan Feb Mar
Apr May Jun
Jul Aug
Jan Feb Mar
Apr May Jun
Jul Aug
Infected
Critically colonised
No infection present 
although patient 
remained at high risk 
of recurrence
Wound bioburden levels 2012 Wound bioburden levels 2013
Wounds UK | Vol 11 | No 3 | 2015 37
RESEARCH AND AUDIT
required silver antimicrobial dressings, antibiotics 
and regular wound swabs. Dressings were changed 
three times per week and compression bandaging 
was used to control venous hypertension and 
the subsequent high levels of exudate. Due to the 
patient’s underlying disease, it was imperative that 
he remained free from infection. Although healing 
is desirable, the main objective for the nursing team 
was to maintain the patient’s safety and comfort. 
Preventing the need for repeated use of antibiotics 
also reduces the risk of development of antibiotic 
resistance and other associated complications, i.e. 
Clostridium difficile infections. It was therefore 
decided to enter the patient onto the pathway in 
January 2013.
Retrospective data pertaining to incidence of 
infection was obtained from the patient's nursing 
records between the period of January to August 2012 
and compared with the same period in 2013 (Figure 
6). During the 2012 period, the wound remained 
either critically colonised or infected. However, 
during the same period in 2013, there was a significant 
reduction in the periods of infection (April and 
August); for the remainder of the treatment period, 
the wound remained infection free.
Additionally, there was a reduced spend on 
primary dressings of £447.53. For the patient, 
effective prophylactic management of wound 
bioburden has improved the potential for healing 
(Figures 7 and 8). This has led to the patient 
now being able to participate in his own care, 
including one dressing change plus removal 
and re-application of compression hosiery, 
promoting independence and quality of life. Clinic 
appointments have reduced to weekly. W
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